Mannose binding lectin (MBL) deficiency may be associated with increased susceptibility to infection and autoimmune disorders, such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). In the present study, we performed for the first systematic search for mutations in all the four exons of the MBL gene using polymerase chain reaction (PCR)/single-strand conformation polymorphism (SSCP) analysis. Of 49 healthy Japanese individuals studied, only the previously reported mutation at the codon 54 (substitution from Gly to Asp; G54D) was identified. The allele frequencies of G54D in 105 healthy Japanese individuals, 95 SLE patients and 59 RA patients, were 0.233, 0.226 and 0.178, respectively, which were not significantly different. In addition, two polymorhisms at positions of −550 and −221 in the promoter region were not associated with SLE and RA. It is unlikely that MBL deficiency plays a major role in the pathogenesis of SLE and RA in Japanese. Genes and Immunity (2000) 1, 464-466.
Mannose binding lectin (MBL), also known as mannose or mannan binding protein, is a member of the collectin family of proteins, characterized by the presence of collagen-like domains and carbohydrate recognition lectin domains. 1 MBL binds to high mannose and Nacetyl-glucosamine oligosaccharides present on the cell surface of yeasts, bacteria and viruses and serves as the initiator of the third pathway of complement system (lectin pathway). 2 MBL is considered to be involved in the innante immunity of host defence that works prior to the establishment of adaptive immune system. Previous studies suggest that homozygous deficiency of MBL is associated with recurrent infections in children 3, 4 as well as increased susceptibility and shorter survival of human immunodeficiency virus (HIV) patients. 5, 6 Although there are controversies, association of MBL deficiency with chronic hepatitis virus type B (HBV) infection 7 and its progression, 8 and with poor response to interferon in chronic hepatitis virus type C (HCV) 9 has also been reported. In addition MBL deficiency has also been implicated in the pathogenesis of autoimmune diseases. Studies in the UK and Spanish populations, as well as in Hong Kong Chinese have suggested the association of MBL deficiency with systemic lupus erythematosus (SLE). [10] [11] [12] In the case of rheumatoid arthritis (RA), results are controversial. Presence 13 or absence 14, 15 of association of MBL deficiency with RA have been reported.
The serum concentration of MBL is dependent on various factors such as the mutations in the coding region, polymorphisms in the promoter region, ethnicity and age. 16, 17 The most important determinant is the mutations in the coding region. So far, three structural mutations have been described at codons 52, 54 and 57 in the MBL gene, all of which are caused by a single amino acid substitution and result in the profound reduced levels of MBL (MBL deficiency) in the homozygous individuals. 16 Considering the importance of MBL in the immune system, further study is needed to identify additional structural mutations of MBL that cause not only the quantitative reduction but also the dysfunction in the complement activation. We first analyzed all the four exons and their flanking introns for mutations or polymorphisms at the molecular level by polymerase chain reaction (PCR)/single-strand conformation polymorphism (SSCP) analysis using intron-based exon-specific primers which was based on the MBL genomic sequences. 18 The primer sequences were:-5′-CTGAGATTAACCTTCCCTGAGT-3′ and 5′-AGAATTGCAGAGACAGAACAGC-3′ for exon 1 (product size 265 bp);
5′-GGGCATCAAACTCTTGAAGAGA-3′ and 5′-GGTGAAGTCAGCTCAGACCTT-3′ for exon 2 (222 bp); 5′-TTCTGAGGCTCCTTCTCAACAA-3′ and 5′-TTCAAGCTGCCTGGAGAGTAA-3′ for exon 3 (155 bp); 5′-GGCTTAAGGATGAGTGAGTTTC-3′ and 5′-TCTGTCTTCTCATCATCAGTGATGC-3′ for exon 4-1 (215 bp);] 5′-AGAATCTCATCAAGGAGGAAGC-3′ and 5′-AAAGACAAGGAGGGCCTGAGT-3′ for exon 4-2 (226 bp).
In order to keep the size of PCR products appropriate for SSCP analysis, exon 4 was divided into two fragments, exon 4-1 and 4-2. In addition, we analyzed whether the frequency of structural mutations of MBL is increased in the Japanese patients with SLE and RA. Of 49 healthy Japanese individuals studied, only a known mutation at amino acid residue 54 was identified. Namely, the second nucleotide G of the codon GGC for Gly (amino acid residue 54) was substituted for A, which resulted in the amino acid change from Gly to Asp (G54D). The other two known mutations at codons 52 and 57 as well as novel mutations or polymorphisms were not identified in the entire MBL gene. The allele frequency of this G54D mutation was assessed by the migration pattern of the the PCR product of exon 1. Table 1 shows the allele frequencies of G54D of our 105 healthy individuals, 95 SLE patients (87 females, 8 males) and 59 RA patients (51 females, 8 males), all of whom were Japanese. The frequency of homozygous and heterozygous G54D mutation in our 105 healthy individuals was 9.5% and 27.6% with the allele frequency of 0.233, which was almost completely identical with those in the previous report in the Japanese 218 healthy individuals. 9 It is likely that the incidence of G54D mutation is more frequent in Japanese than those in the Caucasians and Hong Kong Chinese whose ranges are reported to be 0.11 to 0.16. 16 In Africans, the G54D mutation is not common (less than 0.03) and the mutation at codon 57 (G57E) occurs at comparable frequencies with the range of 0.23 to 0.29. 16 Such a high frequency of MBL deficiency might be caused by selective advantage. It is probable that the severity in inflammation might rather be attenuated in the absence of MBL as has been suggested in the case of terminal complement component deficiencies. 19 In order to confirm that the MBL gene mutation other than G54D is rare, restriction fragment length polymorphism (RFLP) analysis by using MboII was performed for codon 57 in all of the subjects (105 health individuals 95 SLE patientsand 59 RA patients). As for codon 52 mutation, sequencing analysis of the DNA from the 95 SLE patients were 20 The mechanism(s) by which the complement deficiency contribute to the pathogenesis of SLE are unclear, however there have been reported several explanations, such as impaired clearance of immune complexes and apoptotic cells that would lead to enhanced autoantibody production. 21 Based on the findings that MBL is structurally and functionally analogous to C1q, the association of MBL deficiency with SLE has been investigated in various ethnic groups. In the study of 102 SLE patients in the UK, and 111 Chinese SLE patients in Hong Kong, there was a modest but statistically not significant increase in the frequency of G54D mutation (0.25 in SLE patients vs 0.19 in controls; odds ratio 1.5 and 0.17 in SLE patients vs 0.11 in controls; odds ratio 1.7). 10, 12 In the 50 Spanish SLE patients, a significant increase in the G54D frequency (0.28 in SLE patients vs 0.16 in controls) has been reported. 11 However, the allele frequency of G54D mutation in our 95 SLE patients was 0.226 that was comparable to the frequency of 0.233 in controls. Moreover. The frequency of homozygous G54D mutation was even decreased in SLE (1.1%: 1/95) when compared with that in controls (9.5%: 10/105) (P Ͻ 0.01) ( 2 test). It is not probable that the decreased incidence of G54D homozygote in SLE patients reflects the fatal infection caused by the treatment of SLE with immunosuppressant, because two patients who enrolled in the study but died during the study period were either a homozygote of the wildtype MBL (Glycine at amino acid residue 54) or a heterozygote for the G54D mutation. Although further multicenter study is needed, these results suggest that MBL deficiency would not be a risk factor for Japanese SLE.
Agalactosyl IgG associated with RA have been shown to activate complement via the MBL and was directly implicated in the pathogenesis of RA in an animal model. 22, 23 Thus, it can be hypothesized that MBL deficiency might interfere with the activation of complement system by agalactosyl IgG and might be protective in the development of RA. However, recent studies indicated that there was either no association of MBL deficiency and RA 14, 15 or even an increased risk for RA has been demonstrated in MBL deficiency. 13 In our RA patients, the allele frequency of G54D mutation (0.178) as well as the incidences of the homozygotes (6.8%; 4/59) and the heterozygotes (22.0%; 13/59) of G54D displayed no significant statistical differences compared to those of controls when assessed by 2 test. In addition, the age of RA onset or the severity of disease assessed by the neccessity of joint replacement were not significantly different in the patients either carrying G54D allele or not.
There have been reported two polymorphisms at positions −550 (H/L variants) and −221 (X/Y variants) in the promoter region of the MBL gene. 17 The promoter haplotypes, HY, LY, and LX are associated with high, medium, and low levels of MBL serum concentrations, while the structural mutations are associated with complete loss of the serum protein level. The promoter polymorphisms of our subjects were investigated according to the methods described previously. 24 The allele frequencies of HY, LY, and LX were 0.538, 0.390, and 0.071, respectively in 105 controls; 0.521, 0.389, and 0.089, respectively in 95 SLE patients; 0.500, 0.423. and 0.076 in 59 RA patients. HX allele was not identified in our subjects and G54D mutation was completely in linkage disequilibrium with LY allele. It is thus concluded that the promoter polymorphisms of MBL are not associated with SLE or RA. The association of MBL promoter polymorphisms with SLE has been reported in Hong Kong Chinese, 24 while in Caucasians, the genetic polymorphisms in the promoter region as well as the structural variants in exon 1 are not significant risk factors for SLE. 25 In conclusion, the present study showed that by using PCR/SSCP analysis of all the four exons of the MBL gene, only G54D mutation is common in Japanese and the other mutations including those previously reported in other ethnic groups are rare. In addition, G54D mutation was not associated with our SLE and RA patients. The genetic frequencies of the two known polymorphisms in the MBL gene were not associated with the increased risk of the SLE and RA patients as well. It is unlikely that MBL deficiency plays a major role in the pathogenesis of these autoimmune disorders in Japanese.
